EMD-22494
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation)
EMD-22494
Single-particle3.0 Å

Map released: 14/10/2020
Last modified: 06/11/2024
Sample Organism:
Homo sapiens,
Severe acute respiratory syndrome coronavirus 2
Sample: SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment
Fitted models: 7jv6 (Avg. Q-score: 0.433)
Deposition Authors: Park YJ
,
Tortorici MA,
Walls AC
,
Czudnochowski N,
Snell G,
Veesler D
Sample: SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment
Fitted models: 7jv6 (Avg. Q-score: 0.433)
Deposition Authors: Park YJ


Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Piccoli L,
Park YJ
,
Tortorici MA,
Czudnochowski N,
Walls AC
,
Beltramello M,
Silacci-Fregni C,
Pinto D,
Rosen LE
,
Bowen JE
,
Acton OJ
,
Jaconi S,
Guarino B
,
Minola A,
Zatta F
,
Sprugasci N,
Bassi J,
Peter A,
De Marco A,
Nix JC,
Mele F,
Jovic S,
Rodriguez BF,
Gupta SV,
Jin F,
Piumatti G,
Lo Presti G,
Pellanda AF,
Biggiogero M,
Tarkowski M,
Pizzuto MS
,
Cameroni E,
Havenar-Daughton C,
Smithey M,
Hong D,
Lepori V,
Albanese E,
Ceschi A
,
Bernasconi E
,
Elzi L
,
Ferrari P
,
Garzoni C,
Riva A
,
Snell G,
Sallusto F
,
Fink K,
Virgin HW
,
Lanzavecchia A,
Corti D
,
Veesler D
(2020) Cell , 183 , 1024 - 1042.e21
















(2020) Cell , 183 , 1024 - 1042.e21
Abstract:
Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune protection and identifying targets for vaccine design. In a cohort of 647 SARS-CoV-2-infected subjects, we found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera. Whereas overall RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased over time for some individuals, consistent with affinity maturation. We structurally defined an RBD antigenic map and serologically quantified serum Abs specific for distinct RBD epitopes leading to the identification of two major receptor-binding motif antigenic sites. Our results explain the immunodominance of the receptor-binding motif and will guide the design of COVID-19 vaccines and therapeutics.
Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune protection and identifying targets for vaccine design. In a cohort of 647 SARS-CoV-2-infected subjects, we found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera. Whereas overall RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased over time for some individuals, consistent with affinity maturation. We structurally defined an RBD antigenic map and serologically quantified serum Abs specific for distinct RBD epitopes leading to the identification of two major receptor-binding motif antigenic sites. Our results explain the immunodominance of the receptor-binding motif and will guide the design of COVID-19 vaccines and therapeutics.